Nanostics and Protean BioDiagnostics Partner to Launch CDX Prostate for Men at Risk of Having Aggressive Prostate Cancer in the United States

In Today’s News: Nanostics Inc. and Protean BioDiagnostics have partnered to launch CDX Prostate in the United States for men at risk of aggressive prostate cancer. This blood-based diagnostic tool utilizes AI-powered learning to help healthcare providers determine the risk…



